TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37269841

Group type: EXPERIMENTAL
Intervention: Lutetium-177 PSMA-targeted radioligand therapy
Number of subjects: 831

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 831
Study: 37269870

Group type: EXPERIMENTAL
Intervention: Nangibotide 0.3 mg/kg per h (low-dose group)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Nangibotide 1.0 mg/kg per h (high-dose group)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: All groups (placebo, low-dose, high-dose)
Number of subjects: 355
Study: 37269872

Group type: EXPERIMENTAL
Intervention: CADe-assisted colonoscopy (GI Genius 2.0.2; Medtronic)
Number of subjects: 2015

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 2015
Study: 37269883

Group type: EXPERIMENTAL
Intervention: Gamification (presence of gamification with low budget)
Number of subjects: 1228

Group type: COMPARATOR
Intervention: No gamification (absence of gamification with low budget)
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Budget amount ($50 vs. $30)
Number of subjects: 1228
Study: 37269904

Group type: EXPERIMENTAL
Intervention: anti-programmed cell death protein 1 ± anti-cytotoxic T-lymphocyte-associated protein 4
Number of subjects: 116
Study: 37269909

Group type: EXPERIMENTAL
Intervention: Low dose blueberry powder (2.5%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium dose blueberry powder (5%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 37269941

Group type: EXPERIMENTAL
Intervention: Group A: 0.5 mg/kg once daily for 14 days
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Group B: 1 mg/kg once daily for 7 days
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Group C: 1 mg/kg twice daily for 3.5 days
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 73
Study: 37270027

Group type: EXPERIMENTAL
Intervention: Exclusive Breastfeeding (EBF)
Number of subjects: 1989

Group type: EXPERIMENTAL
Intervention: Breastfeeding with at least 1 daily meal of Cows' Milk Formula (CMF)
Number of subjects: 1989

Group type: COMPARATOR
Intervention: Cows' Milk Formula (CMF) only
Number of subjects: 1989
Study: 37270188

Group type: EXPERIMENTAL
Intervention: Eye-movement desensitisation and reprocessing therapy (EMDR) plus standard neuropsychiatric care (NPC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard neuropsychiatric care (NPC)
Number of subjects: 50
Study: 37270190

Group type: EXPERIMENTAL
Intervention: Psychotherapy delivered by psychologists
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Therapist responsiveness to client characteristics and preferences
Number of subjects: 573
Study: 37270195

Group type: EXPERIMENTAL
Intervention: 12 week pulmonary rehabilitation (PR) programme in primary care, supervised by a physiotherapist
Number of subjects: 134

Group type: COMPARATOR
Intervention: No pulmonary rehabilitation (control group)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 12 week pulmonary rehabilitation (PR) programme
Number of subjects: 134
Study: 37270194

Group type: EXPERIMENTAL
Intervention: CT perfusion (CTP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard Targeted Temperature Management
Number of subjects: 90
Study: 37270201

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 15480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15480

Group type: EXPERIMENTAL
Intervention: Routine data (Aspirin)
Number of subjects: 15480

Group type: COMPARATOR
Intervention: Routine data (Placebo)
Number of subjects: 15480
Study: 37270289

Group type: EXPERIMENTAL
Intervention: Teduglutide 0.05 mg/kg/d for 48 weeks
Number of subjects: 25
Study: 37270291

Group type: EXPERIMENTAL
Intervention: Spot urine samples collected from women in Switzerland
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Spot urine samples collected from women in South Africa
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Spot urine samples collected from women in Tanzania
Number of subjects: 308
Study: 37270471

Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization (IASTM)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Myofascial release therapy (MRT)
Number of subjects: 33
Study: 37270517

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg twice daily for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 37270692

Group type: EXPERIMENTAL
Intervention: Encorafenib plus binimetinib
Number of subjects: 98
Study: 37270691

Group type: EXPERIMENTAL
Intervention: Neoadjuvant FOLFOX (6 cycles over 12 weeks)
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Neoadjuvant 5FUCRT (28 fractions over 5.5 weeks)
Number of subjects: 1194
Study: 37270698

Group type: EXPERIMENTAL
Intervention: Tepotinib, 500 mg once daily
Number of subjects: 313
Study: 37270762

Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional uninformed parametric models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informed Bayesian survival models
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uninformed log-normal model
Number of subjects: 0
Study: 37270840

Group type: EXPERIMENTAL
Intervention: Melancholic depression (MD) patients
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Nonmelancholic depression (NMD) patients
Number of subjects: 227

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 227
Study: 37271020

Group type: EXPERIMENTAL
Intervention: Exercise Training Rehabilitation (ETR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard Physiotherapy (SP)
Number of subjects: 60
Study: 37271067

Group type: EXPERIMENTAL
Intervention: Very-Low-Calorie Diet (VLCD) for 2 weeks preoperatively
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard procedural fasting
Number of subjects: 53
Study: 37271356

Group type: EXPERIMENTAL
Intervention: Preventive PCI plus optimal medical therapy (OMT)
Number of subjects: 1608

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 1608
Study: 37271412

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 3600 mg per day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 37271416

Group type: EXPERIMENTAL
Intervention: 60-mg ferrous sulfate
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 18-mg ferrous bisglycinate
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Comparison of iron groups
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 480
Study: 37271418

Group type: EXPERIMENTAL
Intervention: Atrophy in the medial temporal lobe and subregions of the motor and prefrontal cortex
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Widespread reduced white matter integrity
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Overall associations
Number of subjects: 283
Study: 37271576

Group type: EXPERIMENTAL
Intervention: Food tracking adherence of 28.5% of intervention days
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Food tracking adherence of 39.4% of intervention days
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Food tracking adherence of 67.1% of intervention days
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Food tracking trajectories identified through time series clustering
Number of subjects: 153
Study: 37271593

Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 37271594

Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: High lipidic burden
Number of subjects: 1346

Group type: COMPARATOR
Intervention: White patients
Number of subjects: 1346
Study: 37271703

Group type: EXPERIMENTAL
Intervention: AZD1222 (ChAdOx1 nCoV-19)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 37271706

Group type: EXPERIMENTAL
Intervention: Fourth dose of NVX-CoV2373 (5 µg rS protein + 50 µg Matrix-M adjuvant)
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Third dose of NVX-CoV2373
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Fourth dose of NVX-CoV2373
Number of subjects: 1283

Group type: COMPARATOR
Intervention: Primary series of NVX-CoV2373
Number of subjects: 1283
Study: 37271721

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 107

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 107
Study: 37271818

Group type: EXPERIMENTAL
Intervention: Ivermectin mass drug administration to humans and/or livestock
Number of subjects: 131818

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 131818
Study: 37271980

Group type: EXPERIMENTAL
Intervention: Nasal Polyposis Symptom Diary (NPSD)
Number of subjects: 518

Group type: COMPARATOR
Intervention: 22-item Sino-Nasal Outcome Test (SNOT-22)
Number of subjects: 518
Study: 37272079

Group type: EXPERIMENTAL
Intervention: Ari 2MRTU 960
Number of subjects: 81

Group type: COMPARATOR
Intervention: AOM 400
Number of subjects: 81
Study: 37272245

Group type: EXPERIMENTAL
Intervention: Multiparametric MRI (DCE-MRI + DW-MRI)
Number of subjects: 1678

Group type: COMPARATOR
Intervention: DCE-MRI
Number of subjects: 1678
Study: 37272375

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Guselkumab 100 mg
Number of subjects: 40
Study: 37272479

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet (LFD) combined with gluten-free diet (GFD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gluten-free diet (GFD)
Number of subjects: 0
Study: 37272512

Group type: EXPERIMENTAL
Intervention: Cilta-cel
Number of subjects: 419

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 419
Study: 37272513

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (200 mg) plus cisplatin-based chemotherapy for 4 cycles, followed by surgery and adjuvant pembrolizumab (200 mg) for up to 13 cycles.
Number of subjects: 797

Group type: COMPARATOR
Intervention: Placebo plus cisplatin-based chemotherapy for 4 cycles, followed by surgery and placebo for up to 13 cycles.
Number of subjects: 797
Study: 37272516

Group type: EXPERIMENTAL
Intervention: Vorasidenib (40 mg once daily)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 37272521

Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg) subcutaneously once every 2 weeks
Number of subjects: 939

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 939
Study: 37272527

Group type: EXPERIMENTAL
Intervention: Axi-cabtagene ciloleucel (axi-cel)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 359
Study: 37272534

Group type: EXPERIMENTAL
Intervention: Neoadjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin)
Number of subjects: 1128

Group type: COMPARATOR
Intervention: Chemoradiotherapy
Number of subjects: 1128
Study: 37272540

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg/day for five days at months 0 and 12
Number of subjects: 1713

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 24 mg/day for three days at months 12 and 24
Number of subjects: 1713
Study: 37272535

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily)
Number of subjects: 682

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 682
Study: 37272947

Group type: EXPERIMENTAL
Intervention: Ciprofol
Number of subjects: 135

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 135
Study: 37272981

Group type: EXPERIMENTAL
Intervention: Structural Moral Case Deliberation (MCD)
Number of subjects: 435

Group type: COMPARATOR
Intervention: No Structural MCD
Number of subjects: 435
Study: 37273224

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (NTG) 0.2-0.6 mg/h
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 37273273

Group type: EXPERIMENTAL
Intervention: Animal-assisted group psychotherapy (including horses, rabbits, chickens, goats, and a dog)
Number of subjects: 3
Study: 37273420

Group type: EXPERIMENTAL
Intervention: Ceralasertib monotherapy 160 mg BID continuously
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg BID followed by ceralasertib 160 mg BID 1 week on/3 weeks off
Number of subjects: 11
Study: 37273449

Group type: EXPERIMENTAL
Intervention: 150 mg oral risedronate for six months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo capsules for six months
Number of subjects: 24
Study: 37273518

Group type: EXPERIMENTAL
Intervention: Fluoroscopy-free direct solitary cholangioscopy (DSC)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard endoscopic retrograde cholangiography (ERC)
Number of subjects: 47
Study: 37273658

Group type: EXPERIMENTAL
Intervention: Community-based physical activity programming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wellness counseling
Number of subjects: 0
Study: 37273703

Group type: EXPERIMENTAL
Intervention: Expert Patient Program Catalonia™ (EPPC-MS)
Number of subjects: 144
Study: 37273933

Group type: EXPERIMENTAL
Intervention: Eight-week transdiagnostic stand-alone internet-based CBT intervention for assertiveness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37273934

Group type: EXPERIMENTAL
Intervention: eHealth ecosystem of stepped and personalized psychosocial care for 9 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study: 37273942

Group type: EXPERIMENTAL
Intervention: Ulotaront (25, 50, or 75 mg/d)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 37275501

Group type: EXPERIMENTAL
Intervention: Salt Liz (75% sodium and 25% potassium)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Salt Liz
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Educational entertainment activities
Number of subjects: 60
Study: 37275631

Group type: EXPERIMENTAL
Intervention: Early introduction of standardized complementary food (10-12 weeks corrected for gestational age)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Late introduction of standardized complementary food (16-18 weeks corrected for gestational age)
Number of subjects: 177
Study: 37275659

Group type: EXPERIMENTAL
Intervention: Living in a private nursing home
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Having suffered a stroke
Number of subjects: 78
Study: 37275884

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy plus PD-1 blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemoradiotherapy alone
Number of subjects: 0
Study: 37275927

Group type: EXPERIMENTAL
Intervention: Level I axillary dissection
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Level II axillary dissection
Number of subjects: 61
Study: 37275956

Group type: EXPERIMENTAL
Intervention: Argan spinosa oil
Number of subjects: 140

Group type: COMPARATOR
Intervention: 1% hydrocortisone ointment
Number of subjects: 140
Study: 37275963

Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy (ET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ribociclib (600-mg/day)
Number of subjects: 0
Study: 37275983

Group type: EXPERIMENTAL
Intervention: Bipolar disorder patients with higher hospitalization times
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Bipolar disorder patients with more hospitalization times
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Management of depressive episode and functional rehabilitation
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Suicide times
Number of subjects: 520
Study: 37276032

Group type: EXPERIMENTAL
Intervention: Kool Kit (KK)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Arctic Sun with adhesive ArcticGel pads (AS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Blanketrol III with two nonadhesive Maxi-Therm Lite blankets (BL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Blanketrol III with nonadhesive Kool Kit (KK)
Number of subjects: 8
Study: 37276053

Group type: EXPERIMENTAL
Intervention: Triheptanoin in triheptanoin-naïve cohort
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Triheptanoin in CL201 rollover cohort
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Triheptanoin in IST/EAP cohort
Number of subjects: 94
Study: 37276067

Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg every 3 weeks (Cohort 3)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg every 3 weeks (Cohort 1)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg every 3 weeks (Cohort 2)
Number of subjects: 77
Study: 37276084

Group type: EXPERIMENTAL
Intervention: Behavioral activation therapy (BA)
Number of subjects: 39
Study: 37276086

Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted psychotherapy
Number of subjects: 13
Study: 37276273

Group type: EXPERIMENTAL
Intervention: MI combined with physical practice of walking
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Two different gait training protocols
Number of subjects: 30
Study: 37276451

Group type: EXPERIMENTAL
Intervention: Pegaspargase 2000 IU/m2 added to courses 1, 2, 5, and 6 of an 8-block chemotherapy protocol.
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Pegaspargase treatment with allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 203

Group type: COMPARATOR
Intervention: HCT (control group)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Age and MRD status as independent factors
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Pegaspargase treatment
Number of subjects: 203
Study: 37276496

Group type: EXPERIMENTAL
Intervention: MS2010-SR (anthracycline-free protocol)
Number of subjects: 369

Group type: COMPARATOR
Intervention: MS2003-SR (modified Berlin-Frankfurt-Muenster ALL-IC2002 protocol with 120 mg/m² anthracycline)
Number of subjects: 369
Study: 37276510

Group type: EXPERIMENTAL
Intervention: Guadecitabine
Number of subjects: 815

Group type: COMPARATOR
Intervention: Treatment Choice (TC) - azacitidine, decitabine, or low-dose cytarabine
Number of subjects: 815

Group type: COMPARATOR
Intervention: Treatment Choice (TC)
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Guadecitabine (in patients receiving ≥4 cycles)
Number of subjects: 815

Group type: COMPARATOR
Intervention: Treatment Choice (TC) (in patients receiving ≥4 cycles)
Number of subjects: 815
Study: 37276590

Group type: EXPERIMENTAL
Intervention: STRIDE (AssiSTed EaRly MobIlity for HospitalizeD VEterans) walking program
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (pre-STRIDE time periods)
Number of subjects: 8
Study: 37276871

Group type: EXPERIMENTAL
Intervention: Zanidatamab 20 mg/kg intravenously every 2 weeks
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Zanidatamab
Number of subjects: 87
Study: 37276913

Group type: EXPERIMENTAL
Intervention: Half-dose quadruple therapy (irbesartan 75 mg + metoprolol 23.75 mg + amlodipine 2.5 mg + indapamide 1.25 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard-dose dual therapy (irbesartan 150 mg + amlodipine 5 mg)
Number of subjects: 90
Study: 37276937

Group type: EXPERIMENTAL
Intervention: Dietary pattern high in ultraprocessed foods (UPF-DP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dietary pattern void of ultraprocessed foods (UN-DP)
Number of subjects: 20
Study: 37276947

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant follicle-stimulating hormone (rFSH) treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (normal-weight women)
Number of subjects: 54
Study: 37277078

Group type: EXPERIMENTAL
Intervention: TC-325
Number of subjects: 106

Group type: COMPARATOR
Intervention: SET
Number of subjects: 106
Study: 37277100

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard reminiscence therapy
Number of subjects: 0
Study: 37277217

Group type: EXPERIMENTAL
Intervention: Intensive lipid lowering (LDL-C of <1.8 mmol/L or ≥50% reduction from the baseline)
Number of subjects: 2900

Group type: COMPARATOR
Intervention: Moderate-intensity lipid lowering (LDL-C of <2.6 mmol/L or 30%-49% reduction from the baseline)
Number of subjects: 2900
Study: 37277219

Group type: EXPERIMENTAL
Intervention: Rhythm control therapies
Number of subjects: 5560

Group type: COMPARATOR
Intervention: Non-rhythm control strategy
Number of subjects: 5560
Study: 37277227

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Number of subjects: 46
Study: 37277275

Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg BID
Number of subjects: 277
Study: 37277454

Group type: EXPERIMENTAL
Intervention: Camonsertib (RP-3500) at a recommended phase 2 dose of 160 mg weekly on days 1-3
Number of subjects: 120
Study: 37277703

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with 20 ml of bupivacaine 0.25% (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with 20 ml saline injection (n=50)
Number of subjects: 100
Study: 37277833

Group type: EXPERIMENTAL
Intervention: Low-calorie diet plus pelvic floor muscle training (PFMT) protocol for 12 weeks, including 6 group sessions of supervised PFMT delivered by a physiotherapist.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-calorie diet alone for 12 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-calorie diet plus PFMT protocol for 12 weeks.
Number of subjects: 0
Study: 37277837

Group type: COMPARATOR
Intervention: Home visits by gender-matched community health workers (Arm 1)
Number of subjects: 2152

Group type: COMPARATOR
Intervention: Gender-segregated, group discussion sessions (Arm 2)
Number of subjects: 2152

Group type: COMPARATOR
Intervention: Both home visits and group discussion sessions (Arm 3)
Number of subjects: 2152

Group type: EXPERIMENTAL
Intervention: Control group (no intervention)
Number of subjects: 2152
Study: 37277877

Group type: EXPERIMENTAL
Intervention: Minocycline for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 60
Study: 37277878

Group type: EXPERIMENTAL
Intervention: Family Check-Up 4 Health (FCU4Health)
Number of subjects: 113
Study: 37278122

Group type: EXPERIMENTAL
Intervention: HeartLogic algorithm in alert state
Number of subjects: 568

Group type: COMPARATOR
Intervention: HeartLogic algorithm out of alert state
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: HeartLogic alerts
Number of subjects: 568
Study: 37278302

Group type: EXPERIMENTAL
Intervention: HBV-HIV co-infection
Number of subjects: 116

Group type: COMPARATOR
Intervention: HBV mono-infection
Number of subjects: 116